Skip to main content
Healthcare

STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more

STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more

Feed excerpt — reported by STAT News

India proposed rules requiring regulators to immediately suspend manufacturing licenses for drugs that fail quality standards in government testing

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.